Technology

The Future of Life Insurance: Part One

November 3, 2016
​by Jon Sabes, CEO

Epigenetics can predict all-cause mortality. The implications for the Life Insurance industry is nothing if not revolutionary.

Tap to read

The Future of Life Insurance: Part Two​​

​April 19, 2018
by Jon Sabes, CEO

Consumers have the power to experience themselves with transcendent insights that topple generational icons and take them on a singular adventure.​
Tap to read

Life Epigenetics​

The M-Panel testing technology for life expectancy, smoking and alcohol can be found here.​
Visit the site

Interested in learning more?




Frequently Asked Questions

FAQs about the technology and how GWG may integrate it into its business:

What is the technology GWG Holdings has licensed from UCLA? 

We have licensed the “DNA methylation-based predictor of mortality” technology from UCLA that was invented by one of UCLA’s professors, Dr. Steve Horvath, the leading expert on epigenetic technology and aging. Our license is exclusive to life insurance and related businesses, which puts us in a unique position to apply this technology to this industry.

What is this technology? 

The technology, invented by Dr. Steve Horvath, enhances the prediction of life expectancy by using epigenetic biomarkers that can be identified in saliva or blood samples. Epigenetics differs from genetics in that epigenetics do not include changes to the genetic sequence, an important distinction that means we are analyzing material that is not fixed at birth but changes as a person ages and provides insight into life expectancy that has never before been available. Through our subsidiary Life Epigenetics we have been collecting and analyzing epigenetic data from policyholders looking to sell their life insurance and have been actively pursuing the commercialization of the epigenetic-based technology in what is called “M-Panel” technology.

How will it be used and how will it affect GWG Holding’s current business?

We are working to find ways to integrate aspects of this technology into our underwriting protocols to help us make better decisions about the life insurance policies we purchase.

What is your motivation for doing this?

As a leader in the life insurance secondary market for more than ten years, we have had a front row seat to how the key parts of this industry operate. We believe these new technologies possess the potential to upend a century of entrenched incumbent practices in the life insurance, and long-term care businesses.

Will this mean that GWG Holdings will change the process it uses for purchasing life insurance policies on the secondary market?

M-Panel technology is designed to easily adapt to current underwriting processes. The process used for purchasing life insurance remains relatively unchanged. This should also hold true for other companies using our technology. However, as we make advancements in this technology and as more and more data is gathered using it, it could very well lead to significant changes to our companies, and others, underwrite risk. Moreover, it could lead to dramatic improvements in efficiency in the purchasing process.

When do you think you will implement this technology into your current business?  

We are currently rolling out this technology with new applicants in our business.

How is this technology different from the home DNA tests I see online?

Online DNA testing companies differ from our technology in two fundamental ways: (1) they are testing your genetic sequence, which hasn’t changed since you were born, and are testing epigenetic biomarkers, which behave more like other biomarkers that are commonly measured at your doctor’s office (e.g., cholesterol); and (2) they focus on diagnosis and pre-disposition to diseases whereas we focus on a newly discovered aspect of “biological aging.”

Who is involved in this project?

Our subsidiary Life Epigenetics has assembled a team of professionals whose expertise cover epigenetic research, biotechnology, data science, actuarial science and other disciplines.